Date: July 15, 2002

For Release: Immediately

Refer to: Rick Ludwig rludwig@inproteomics.com

John Hurrell jhurrell@inproteomics.com

Telephone 317-278-8185

Hurrell Hired To Head Indiana Proteomics Consortium

Industry Veteran Calls Indiana Home

INDIANAPOLIS—Biotechnology executive John G. R. Hurrell, Ph.D., has been named president of the Indiana Proteomics Consortium. The appointment was announced today by the consortium’s interim director, Rick Ludwig, Ph.D. Hurrell will assume responsibility for the consortium’s programs, provide direction and support for the principal investigators, and develop the essential management infrastructure to provide for the long-term success of the organization.

The Indiana Proteomics Consortium was formed in February 2002 by Indiana University, Purdue University, and Eli Lilly and Company. The vision of the newly formed company is to work to develop novel instrumentation and methodologies to unleash the potential power of the emerging field of proteomics to improve human health.

“The Indiana Proteomics Consortium is off to a great start and we are confident that John is uniquely qualified to lead this organization. John’s broad experience, includes leadership at a major diagnostics company as well as the founding of biotechnology start-ups. His world-class academic credentials in protein sciences in conjunction with his entrepreneurial experience will facilitate the further integration of the two academic and single industrial founders of the consortium,” said Ludwig.

Hurrell has spent 10 of the past 13 years living and working in Indiana, both at Boehringer Mannheim Corp. (now Roche Diagnostics) where he was a vice president from 1989 to 1995 and at FluorRx where he was a cofounder and served as president and CEO from 1996 to 2000. Most recently, Hurrell served as general manager of TriPath Oncology, Inc., based in Research Triangle Park, North Carolina. Hurrell received his doctorate from the University of Melbourne and was a Fullbright Fellow at Harvard Medical School. He maintains dual United States and Australian citizenship.

After a brief transition phase, Ludwig will return to Lilly to assume responsibilities for the coordination of internal and external efforts in proteomics as a member of the Research Technologies and Product Development component. These efforts include Lilly’s participation in the consortium.

The Indiana Proteomics Consortium is uniquely positioned to combine the deep analytical chemistry expertise of Indiana University and Purdue University faculties with the commercial and therapeutic know-how of Lilly. The collaborative and highly synergistic cross-institutional projects are designed to enable the consortium to produce innovative technologies that can be licensed or spun off into new companies. Additional information about the consortium is available at www.inproteomics.com.

###